ENTITY
YiChang HEC ChangJiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical (1558 HK)

137
Analysis
Health Care • China
YiChang HEC ChangJiang Pharmaceutical develops, manufactures, and sells pharmaceutical products, focusing on anti-viral, endocrine and metabolic, and cardiovascular diseases. Key products include Kewei (oseltamivir phosphate), Oumeining (telmisartan), and Ertongshu (benzbromarone). The company was founded in 2001 and is headquartered in Dongguan, China.
more
bullish•Meituan
•12 Nov 2019 11:40

HK Connect Flows: USD 729 Million Inflows into Meituan Since Inclusion

In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...

Logo
554 Views
Share
bullish•Meituan
•04 Nov 2019 17:20

HK Connect Flows: $248m Inflows into Meituan on the First Day of Inclusion

In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...

Logo
506 Views
Share
•21 Oct 2019 12:15

HK Connect Flows: Finally the Inclusion for Xiaomi/Meituan

In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...

Logo
503 Views
Share
bullish•Xiaomi
•07 Oct 2019 09:20

Hong Kong Buyback Weekly: Xiaomi Led the Buybacks (2019-10-04)

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top...

Logo
512 Views
Share
•19 Aug 2019 13:59

HK Connect Ideas: Highlight of Hang Seng Quarterly Review (2019-08-16)

In our weekly HK Connect Snippet series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as...

Logo
631 Views
Share
x